IONS
Ionis Pharmaceuticals, Inc. · Healthcare
Insiders bought $1.1M of Ionis Pharmaceuticals, Inc. in the last 12 months
1 insider bought on 1 day.
IONS over the last year
Largest buyers, last 12 months
IONS after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
311 insider filings since 2016, newest first
Shannon L. Devers · EVP, Chief Human Resources Ofc
Michael R Hayden · Director
C Frank Bennett · EVP and Chief Scientific Officer
Allene M. Diaz · Director
Holly B. Kordasiewicz · EVP and Chief Development Officer
Joseph Klein III · Director
Joseph Baroldi · EVP and Chief Business Officer
Patrick R. O'Neil · EVP CLO & General Counsel
Eugene Schneider · EVP, Chf Clinical Develop Ofcr
Brett P Monia · Chief Executive Officer
Eric Swayze · EVP Research
Holly B. Kordasiewicz · EVP and Chief Development Officer
Spencer R Berthelsen · Director
Spencer R Berthelsen · Director
Brett P Monia · CEO
Joseph Loscalzo · Director
Joseph Klein III · Director
Joseph Baroldi · EVP and Chief Business Officer
B Lynne Parshall · Director
Kyle Jenne · EVP, Chf GL Pdt Str Ofcr
Brian Birchler · EVP, Corp, Development Ops
Joseph Baroldi · EVP and Chief Business Officer
Joseph Klein III · Director
Shannon L. Devers · EVP, Chief HR Ofc
Eugene Schneider · EVP, Chf Clinical Develop Ofcr
Patrick R. O'Neil · EVP CLO, GC
Joseph Loscalzo · Director
Joseph Klein III · Director
Joseph Baroldi · EVP and Chief Business Officer
Allene M. Diaz · Director
Shannon L. Devers · EVP, Chief HR Ofc
C Frank Bennett · EVP and Chief Scientific Officer
B Lynne Parshall · Director
Eric Swayze · EVP Research
Brett P Monia · CEO
Brian Birchler · EVP, Corp, Development Ops
Joseph Baroldi · EVP and Chief Business Officer
Eric Swayze · EVP Research
Eugene Schneider · EVP, Chf Clinical Develop Ofcr
Patrick R. O'Neil · EVP CLO, GC
Brett P Monia · CEO
Elizabeth L Hougen · EVP, Finance, CFO
C Frank Bennett · EVP and Chief Scientific Officer
Shannon L. Devers · EVP, Chief HR Ofc
Kyle Jenne · EVP, Chf GL Pdt Str Ofcr
Brian Birchler · EVP, Corp, Development Ops
Joseph Baroldi · EVP and Chief Business Officer
Eric Swayze · EVP Research
Eugene Schneider · EVP, Chf Clinical Develop Ofcr
Patrick R. O'Neil · EVP CLO, GC
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.